Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer
Zhao J, Fong K, Chan Y, Tey J, Dawood S, Lee S, Finn R, Sundar R, Lim J. Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer. Cancers 2023, 15: 4558. PMID: 37760527, PMCID: PMC10527344, DOI: 10.3390/cancers15184558.Peer-Reviewed Original ResearchProgression-free survivalPost-menopausal patientsIndirect treatment comparisonCDK4/6 inhibitorsHR+/HER2- MBCOS differenceOverall survivalSurvival outcomesEndpoint of progression-free survivalFirst-line aromatase inhibitorsProgression-free survival differenceHR+/HER2- metastatic breast cancerPhase III randomized trialComparison of survival outcomesMetastatic breast cancerKaplan-Meier OSTreatment of patientsCox proportional-hazards modelProportional-hazards modelTreatment comparisonsIndirect pairwise comparisonsMONALEESA-2OS benefitAromatase inhibitorsBreast cancerIndirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2- metastatic breast cancer.
Zhao J, Fong K, Chan Y, Tey J, Dawood S, Lee S, Finn R, Sundar R, Lim J. Indirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2- metastatic breast cancer. Journal Of Clinical Oncology 2023, 41: 1071-1071. DOI: 10.1200/jco.2023.41.16_suppl.1071.Peer-Reviewed Original ResearchProgression-free survivalPost-menopausal patientsIndirect treatment comparisonCDK4/6 inhibitorsPALOMA-2MONARCH 3OS differenceOverall survivalAromatase inhibitorsPatient-level time-to-event dataEndpoint of progression-free survivalFirst-line aromatase inhibitorsProgression-free survival differenceHR+/HER2- metastatic breast cancerHormone receptor positive (HR+)/human epidermal growth factor receptor 2Epidermal growth factor receptor 2Progression-free survival curvesPhase III randomized controlled trialsCDK4/6 inhibitor palbociclibMetastatic breast cancerPhase III studyKaplan-Meier OSCox proportional hazards modelsProportional hazards modelTreatment comparisons